JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Debt-to-Equity : 0.19 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is JW (Cayman) Therapeutics Co Debt-to-Equity?

JW (Cayman) Therapeutics Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $16.95 Mil. JW (Cayman) Therapeutics Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $27.70 Mil. JW (Cayman) Therapeutics Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $235.83 Mil. JW (Cayman) Therapeutics Co's debt to equity for the quarter that ended in Dec. 2023 was 0.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for JW (Cayman) Therapeutics Co's Debt-to-Equity or its related term are showing as below:

JWCTF' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.19 Med: 0.04 Max: 0.19
Current: 0.19

During the past 6 years, the highest Debt-to-Equity Ratio of JW (Cayman) Therapeutics Co was 0.19. The lowest was -0.19. And the median was 0.04.

JWCTF's Debt-to-Equity is ranked worse than
54.93% of 1074 companies
in the Biotechnology industry
Industry Median: 0.145 vs JWCTF: 0.19

JW (Cayman) Therapeutics Co Debt-to-Equity Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Debt-to-Equity Chart

JW (Cayman) Therapeutics Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.08

0.04

0.05

0.12

0.19

JW (Cayman) Therapeutics Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial						0.05	0.06	0.12	0.18	0.19

Competitive Comparison of JW (Cayman) Therapeutics Co's Debt-to-Equity

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Debt-to-Equity falls into.

JW (Cayman) Therapeutics Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

JW (Cayman) Therapeutics Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(16.947	+	27.701)	/	235.825
	=	0.19

JW (Cayman) Therapeutics Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(16.947	+	27.701)	/	235.825
	=	0.19

JW (Cayman) Therapeutics Co (OTCPK:JWCTF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

JW (Cayman) Therapeutics Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

02126:Hong Kong

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Headlines

No Headlines